Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Madan Jagasia
Vanderbilt-Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medical University Vienna
Vienna, Austria
- Klinikum Der Universität Regensburg
Regensburg, Germany
- Nottingham City Hospital
Nottingham, United Kingdom
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Mayo Clinic
Rochester, Minnesota, United States
- the Cleveland Clinic
Cleveland, Ohio, United States
- Vanderbilt-Ingram Cancer Center (vicc)
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Aug 2014
- Primary completion
- 11 Oct 2018
- Completion
- 11 Oct 2018
- Last update posted
- 17 Oct 2019
- Registered enrollment
- 19
- Registry id
- NCT02151539
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.